Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.

Grade Last Price % Change Price Change
grade F 1.91 2.69% 0.05
XTLB closed up 2.69 percent on Friday, January 18, 2019, on 13 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical XTLB trend table...

Date Alert Name Type % Chg
Jan 18 200 DMA Resistance Bearish 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Gapped Up Strength 0.00%
Jan 17 Narrow Range Bar Range Contraction 2.69%
Jan 17 Wide Bands Range Expansion 2.69%
Jan 16 Narrow Range Bar Range Contraction 3.24%
Jan 16 Inside Day Range Contraction 3.24%
Jan 16 Wide Bands Range Expansion 3.24%

Older signals for XTLB ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.
Is XTLB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.94
52 Week Low 1.43
Average Volume 18,798
200-Day Moving Average 1.9986
50-Day Moving Average 2.2155
20-Day Moving Average 1.8135
10-Day Moving Average 1.904
Average True Range 0.1642
ADX 16.15
+DI 33.7146
-DI 24.9554
Chandelier Exit (Long, 3 ATRs ) 1.9074
Chandelier Exit (Short, 3 ATRs ) 1.9226
Upper Bollinger Band 2.1042
Lower Bollinger Band 1.5228
Percent B (%b) 0.67
BandWidth 32.059553
MACD Line -0.0704
MACD Signal Line -0.1
MACD Histogram 0.0296
Fundamentals Value
Market Cap 9.86 Million
Num Shares 5.16 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.74
Price-to-Sales 0.00
Price-to-Book 5.40
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.20
Resistance 3 (R3) 2.22 2.14 2.15
Resistance 2 (R2) 2.14 2.07 2.13 2.13
Resistance 1 (R1) 2.03 2.03 1.99 2.01 2.12
Pivot Point 1.95 1.95 1.94 1.94 1.95
Support 1 (S1) 1.84 1.88 1.80 1.82 1.70
Support 2 (S2) 1.76 1.84 1.75 1.69
Support 3 (S3) 1.65 1.76 1.67
Support 4 (S4) 1.63